About NGM Bio
NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. Our initial R&D focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer.
NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.
Working with our strategic partners Merck and MedImmune, NGM Bio is working to develop a portfolio of high-impact therapeutics for underserved patient populations.
To date, we have generated a pipeline that includes:
- NGM282, an engineered protein variant of FGF19 and wholly-owned clinical candidate for the treatment of bile acid related diseases (BARD) and non-alcoholic steatohepatitis (NASH);
- NGM313, an agonistic antibody of the beta-klotho (KLB)/FGFR1c pathway and development candidate for the treatment of metabolic conditions such as type 2 diabetes, obesity and NASH, which is subject to an exclusive option under our Merck collaboration; and
- NGM386 and NGM395, engineered protein variants of NP201 and development candidates for the treatment of metabolic conditions such as type 2 diabetes, obesity and NASH, which have been licensed by our strategic partner Merck.